Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:22:39.506Z.
Consensus retrieved: 2026-10-06T13:38:27.477Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:22:39.506Z.
Quote observation: 2026-10-06T19:19:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: acb65a17080c98cb556e8dedfcd99ff418fc0d96cba63b9d245ba9f7ac680701
Forward PE Ratio (N/A) = Dated Quote Price ($0.96) / Consensus Forward EPS ($-1.63)
FORWARD PE RATIO
N/A
Lantern Pharma Inc.
Market Cap
$12.28M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Lantern Pharma Inc. (LTRN) | $12.28M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.24M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.22M | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.43M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A |
| IRIDEX Corporation (IRIX)vs › | $11.94M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.76M | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.46M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.96, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.63 | $-1.63 – $-1.63 | 1 | n/m |
| 2027-12-31 | $-2.02 | $-2.02 – $-2.02 | 1 | n/m |
| 2028-12-31 | $-2.11 | $-2.11 – $-2.11 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
